Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 6/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.44 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.44 |
| ▸ | PI4KA | P42356 | 1/20 | 0.44 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | DDO | Q99489 | 1/20 | 0.41 |
| ▸ | APLNR | P35414 | 1/20 | 0.39 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.38 |
| ▸ | G6PD | P11413 | 1/20 | 0.37 |
| ▸ | IDE | P14735 | 1/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.37 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31263591 | 1.00 | PIK3CG (0.44) | PIK3CGPIK3CAPIK3CBPIK3CDPI4KA | |
| SCHEMBL3662570 | 0.80 | APLNR (0.61) | PIK3CGPIK3CDKDM4EMEN1ALDH1A1 | |
| SCHEMBL11638312 | 0.78 | ALDH1A1 (0.50) | KDM4EMEN1ALDH1A1LMNAKMT2A | |
| SCHEMBL28815836 | 0.78 | ALDH1A1 (0.41) | PIK3CGPIK3CAPIK3CBPIK3CDKDM4E | |
| SCHEMBL3064504 | 0.78 | PIK3C3 (0.42) | PIK3CGPIK3CDKDM4EMEN1ALDH1A1 | |
| SCHEMBL2286846 | 0.78 | TNNI3K (0.47) | PIK3CGPIK3CDKDM4EMEN1ALDH1A1 | |
| SCHEMBL1641957 | 0.76 | PTGS2 (0.44) | PIK3CGPIK3CAPIK3CBPIK3CDPI4KA | |
| SCHEMBL2201631 | 0.75 | PTGS2 (0.44) | LMNACYP11B2 | |
| SCHEMBL12534336 | 0.74 | PIK3CG (0.38) | PIK3CGPIK3CAPIK3CBPIK3CDPI4KA | |
| SCHEMBL853773 | 0.74 | PTGS2 (0.48) | PIK3CGPIK3CAPIK3CBPIK3CDPI4KA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260138990-A1 | TRICYCLIC FUSED IMIDAZOLE COMPOUNDS AS CD38 MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4739683-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | Janssen Pharmaceutica NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| EP-4702026-A1 | TRICYCLIC FUSED IMIDAZOLE COMPOUNDS AS CD38 MODULATORS AND USES THEREOF | Aeovian Pharmaceuticals, Inc. (US) | 2026-03-04 | — | — | EP | disclosed |
| EP-4334298-B1 | UREA DERIVATIVES WHICH CAN BE USED TO TREAT CANCER | SCORPION THERAPEUTICS INC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20250250259-A1 | METHODS FOR TREATING CANCER | SCORPION THERAPEUTICS, INC. | 2025-08-07 | — | — | US | disclosed |
| US-12312341-B2 | Methods for treating cancer | SCORPION THERAPEUTICS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| WO-2025008059-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | JANSSEN PHARMACEUTICA NV (BE) | 2025-01-09 | — | — | WO | disclosed |
| US-20240400543-A1 | METHODS FOR TREATING CANCER | SCORPION THERAPEUTICS, INC. | 2024-12-05 | — | — | US | disclosed |
| WO-2024226685-A1 | TRICYCLIC FUSED IMIDAZOLE COMPOUNDS AS CD38 MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| US-20240300939-A1 | UREA DERIVATIVES WHICH CAN BE USED TO TREAT CANCER | SCORPION THERAPEUTICS, INC. | 2024-09-12 | — | — | US | disclosed |
| US-7678823-B2 | N-phenylindoles; oral dosage forms; side effect reduction | Myriad Pharmaceticals, Inc. (US) | 2010-03-16 | — | — | US | disclosed |
| US-7678823-B2 | N-phenylindoles; oral dosage forms; side effect reduction | Myriad Pharmaceticals, Inc. (US) | 2010-03-16 | — | — | US | disclosed |
| US-20090118333-A1 | AMIDES USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-07 | — | — | US | disclosed |
| US-20090118333-A1 | AMIDES USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-07 | — | — | US | disclosed |
| WO-2009049181-A1 | AMIDES USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-04-16 | — | — | WO | disclosed |
| US-20090099179-A1 | COMPOUNDS FOR DISEASES AND DISORDERS | MYRIAD GENETICS, INCORPORATED (US) | 2009-04-16 | — | — | US | disclosed |
| US-20090099179-A1 | COMPOUNDS FOR DISEASES AND DISORDERS | MYRIAD GENETICS, INCORPORATED (US) | 2009-04-16 | — | — | US | disclosed |
| US-20080249135-A1 | N-phenylindoles; oral dosage forms; side effect reduction | MYRIAD GENETICS, INCORPORATED (US) | 2008-10-09 | — | — | US | disclosed |
| US-20080249135-A1 | N-phenylindoles; oral dosage forms; side effect reduction | MYRIAD GENETICS, INCORPORATED (US) | 2008-10-09 | — | — | US | disclosed |
| WO-2007115306-A2 | COMPOUNDS FOR DISEASES AND DISORDERS | MYRIAD GENETICS, INC. (US) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260138990-A1 | TRICYCLIC FUSED IMIDAZOLE COMPOUNDS AS CD38 MODULATORS AND USES THEREOF | CD38, BCL9, BCL6B | PIK3CG 2883/4885PIK3CA 2294/4885PIK3CB 2844/4885 |
| US-20240300939-A1 | UREA DERIVATIVES WHICH CAN BE USED TO TREAT CANCER | PIK3CA, PIK3CG, PIK3CD | PIK3CG 2/4885PIK3CA 1/4885PIK3CB 4/4885 |
| US-20090099179-A1 | COMPOUNDS FOR DISEASES AND DISORDERS | CLN6, NLN, CLTC | PIK3CG 1770/4885PIK3CA 2807/4885PIK3CB 1251/4885 |
| US-12312341-B2 | Methods for treating cancer | PIK3CA, PTEN, BRCA1 | PIK3CG 5/4885PIK3CA 1/4885PIK3CB 6/4885 |
| US-20080249135-A1 | N-phenylindoles; oral dosage forms; side effect reduction | NCL, PSEN2, CCNO | PIK3CG 3454/4885PIK3CA 3832/4885PIK3CB 3205/4885 |
| US-20090118333-A1 | AMIDES USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | SCN1A, SCN5A, CACNA1B | PIK3CG 786/4885PIK3CA 1106/4885PIK3CB 1120/4885 |
| US-20250250259-A1 | METHODS FOR TREATING CANCER | PIK3CA, PTEN, BRCA1 | PIK3CG 5/4885PIK3CA 1/4885PIK3CB 6/4885 |
| US-20240400543-A1 | METHODS FOR TREATING CANCER | PIK3CA, PTEN, BRCA1 | PIK3CG 5/4885PIK3CA 1/4885PIK3CB 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.